-
1 month ago | 
onlinelibrary.wiley.com | Stefan Anker |Michele Robertson |John McMurray |Pardeep S. Jhund
Supporting Information Filename Description ejhf3670-sup-0001-supinfo.docxWord 2007 document , 24.6 KB Appendix S1. Supporting Information. References 1, , , , , , et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Statistical methods for recurrent event analysis in cohort studies of CKD. Clin J Am Soc Nephrol 2017; 12: 2066–2073. https://doi.org/10.2215/CJN.12841216 2, .
-
Jan 27, 2025 | 
onlinelibrary.wiley.com | Nicolas Girerd |Université de Lorraine |Pardeep S. Jhund
Invited Editorial Withdrawal of medical therapy for heart failure after rhythm control in arrhythmia-induced cardiomyopathy—a call for caution Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction Luis Manuel Domínguez-Rodríguez, David Dobarro, Carla Iglesias-Otero, María G.
-
Jan 10, 2025 | 
onlinelibrary.wiley.com | Joanna Osmanska |Kieran F. Docherty |Colin Berry |Pardeep S. Jhund
Introduction Accurately estimating left ventricular (LV) filling pressure is crucial for guiding effective treatment decisions. Invasively measured pulmonary capillary wedge pressure (PCWP) is the gold standard method of indirectly estimating LV filling pressure. However, the routine invasive measurement of PCWP is limited by the availability of right heart catheterization and the risk of procedure-related complications.
-
Nov 2, 2024 | 
jacc.org | Shingo Matsumoto |Pardeep S. Jhund |Alasdair Henderson |Johann Bauersachs
IntroductionKidney dysfunction often leads to reluctance to continue disease-modifying therapies in patients with heart failure (HF).
-
Oct 28, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Oct 11, 2024 | 
jacc.org | Jawad H. Butt |Alasdair Henderson |Pardeep S. Jhund |Brian Claggett
Introduction Aldosterone is secreted by the adrenal glands and regulated by circulating angiotensin II and serum potassium concentration, and the deleterious consequences of excessive production of this hormone (and mineralocorticoid receptor overactivation) on the heart, vasculature, and kidney are well-established.1-5 However, aldosterone synthase is also expressed in adipocytes, which can secrete aldosterone, and angiotensin II is produced in adipose tissue and stimulates the production of...
-
Oct 7, 2024 | 
jamanetwork.com | Li Shen |Pardeep S. Jhund |Christopher B Granger |Inder Anand
Evaluating Tools for Assessing Bias in a Meta-Analysis of Clinical Trials on Race and RAS Blockade—Reply Benefit of RAS Blockade in Heart Failure by Race Li Shen, MBChB, PhD; Matthew M. Y. Lee, MBChB, PhD; Pardeep S. Jhund, MBChB, MSc, PhD; Christopher B. Granger, MD; Inder S. Anand, MD, PhD; Aldo P. Maggioni, MD; Marc A. Pfeffer, MD, PhD; Scott D. Solomon, MD; Karl Swedberg, MD, PhD; Salim Yusuf, DPhil; John J. V.
-
Sep 30, 2024 | 
jamanetwork.com | Brian Claggett |Muthiah Vaduganathan |Akshay S. Desai |Pardeep S. Jhund
Key PointsQuestion Do the effects of dapagliflozin on cardiovascular events vary according to baseline kidney function, and does dapagliflozin reduce the rate of estimated glomerular filtration rate (eGFR) decline and kidney outcomes among patients with heart failure and mildly reduced or preserved ejection fraction?
-
Sep 30, 2024 | 
hospitalhealthcare.com | Pardeep S. Jhund
Early and timely recognition of congestion and decompensation may prevent heart failure hospitalisations and improve patient outcomes. But with the clinical signs and symptoms of fluid overload often difficult to elucidate on examination, emerging technological advancements in invasive and non-invasive haemodynamic monitoring are increasingly valuable, as consultant cardiologist Pardeep Jhund discusses.
-
Sep 1, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
